Warning letter
Velocity Pharma LLC [ARCHIVED]: warning letter of Jun 24, 2011
FDA warning letter 157933 · New York District Office
Key facts
| Reference number | 157933 |
|---|---|
| Company | Velocity Pharma LLC [ARCHIVED] |
| Subject | CGMP/Manufacturing, Packaging, Labeling or Holding Operations for Dietary Supplements Regulation/Adulterated |
| Issue date | Jun 24, 2011 |
| Posted date | Jun 24, 2011 |
| Issuing office | New York District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.605, 111, 111.365, 111.453, 111.30(b), 111.75(f), 111.160(d)(1), 111.180(b)(3), 111.180(b)(3)(ii), 111.210(h)(3), 111.260(d), 111.260(j)(1) and 9 more |
| Inspection city | Melville |
| Inspection ZIP | 11747 |
| Inspection start date | Nov 1, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: